Abstract
We used proteomic analyses to assess how drug abuse modulates immunologic responses to infections with the human immunodeficiency virus type 1 (HIV-1). Two dimensional (2D) difference gel electrophoresis was utilized to determine changes in the proteome of peripheral blood mononuclear cells (PBMC) isolated from HIV-1 positive donors that occurred after treatment with cocaine or methamphetamine. Both drugs differentially regulated the expression of several functional classes of proteins. We further isolated specific subpopulations of PBMC to determine which subpopulations were selectively affected by treatment with drugs of abuse. Monocytes, B cells and T cells were positively or negatively selected from PBMC isolated from HIV-1 positive donors. Our results demonstrate that cocaine and methamphetamine modulate gene expression primarily in monocytes and T cells, the primary targets of HIV-1 infection. Proteomic data were validated with quantitative, real-time PCR. These studies elucidate the molecular mechanisms underlying the effects of drugs of abuse on HIV-1 infections. Several functionally relevant classes of proteins were identified as potential mediators of HIV-1 pathogenesis and disease progression associated with drug abuse.
Keywords: cocaine, methamphetamine, peripheral blood mononuclear cells (PBMC), human immunodeficiency virus type 1 (HIV-1), difference gel electrophoresis (DIGE), high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)
Introduction
The human immunodeficiency virus type 1 (HIV-1), a retrovirus, causes the acquired immunodeficiency syndrome (AIDS) which results in immune system collapse rendering the infected patient susceptible to life threatening opportunistic infections and malignancies. Approximately 33.2 million people worldwide are living with HIV-1/AIDS, and 2.5 million people are estimated to have contracted HIV-1 in 2007 (1). In the US, an estimated 1.1 million people are living with HIV-1/AIDS (2). Transmission of HIV-1 generally occurs through infected body fluids (sexual transmission) or parenteral transmission (intravenous drug abusers) (3).
Cocaine and methamphetamine are widely abused drugs, both of which can be snorted, smoked or injected (3). In 2007, the number of new users of cocaine and methamphetamine in the US among persons aged 12 years or older was 906,000 and 157,000, respectively (1–3). From the beginning of the HIV/AIDS epidemic through 2005, an estimated 225,210 cases are believed to be transmitted through injection drug use (1, 5). Current literature suggests that cocaine or methamphetamine usage may exacerbate the immunopathogenesis of HIV-1 (5–8). Cocaine and methamphetamine have both been shown to enhance HIV-1 replication in immune cells including macrophages, dendritic cells and peripheral blood mononuclear cells (PBMC) (9–13). Drug abuse also has been associated with the development of strains of drug resistant HIV-1 (5, 14, 15). Ellis et al. (14) demonstrated that HIV-1 positive methamphetamine users who were receiving highly active anti-retroviral therapy (HAART) had higher viral loads than HIV-1 positive methamphetamine users who were not receiving therapy. Additionally, a dual tropic, multidrug resistant HIV-1 strain was isolated from a methamphetamine user (5). This patient had rapid HIV-1 seroconversion with progression to symptomatic AIDS in 4–20 months. Moreover, antiretroviral naïve patients who use methamphetamine are more likely to have drug resistance to non-nucleoside reverse transcriptase inhibitors than methamphetamine non-users (15).
Understanding how cocaine or methamphetamine modulates the immune response to HIV-1 has not been fully explored. In this paper, we test the hypothesis that cocaine or methamphetamine regulates the expression of various host proteins in PBMC isolated from HIV-1 positive donors. These proteins may directly or indirectly play a role in increased progression of HIV-1 infection. We used 2 Dimensional (2D) difference gel electrophoresis (DIGE) to elucidate the proteomic changes that occurred when PBMC isolated from HIV-1 positive donors were treated with cocaine or methamphetamine. We validated our proteomic results using quantitative real-time PCR. We further investigated which subpopulations of cells were selectively affected by drugs of abuse. Monocytes, B cells and T cells were positively or negatively selected from PBMC isolated from HIV-1 positive donors. Our results demonstrate that cocaine and methamphetamine modulate gene expression primarily in monocytes and T cells.
METHODS
Human Subjects
Blood donors were apprised of this study and consents were obtained consistent with the policies of the appropriate local institutions and the National Institutes of Health. Peripheral blood samples from HIV-1 positive patients were drawn into a syringe containing heparin (20 units/ml). The HIV-1 positive patients were recruited from the Immunodeficiency Services Clinic of the affiliated Erie County (NY) Medical Center.
Isolation of human PBMC
PBMC were isolated by density gradient centrifugation on Ficoll-Paque (Amersham Pharmacia Biotech, Piscataway, NJ). Isolation of PMBC subpopulations: Subpopulations of PBMC were separated using Dynabeads (Invitrogen) according to the manufacturer’s instructions for positive isolation of monocytes (Dynabeads® CD14), positive isolation of B cells (Dynabeads® CD19 Pan B; DETACHaBEAD® CD19), and negative isolation of T cells (Dynabeads® Untouched™ Human T Cells). Cells were cultured in RPMI 1640 medium containing 25 mM HEPES buffer supplemented with 10% heat-inactivated fetal calf serum (Invitrogen, Grand Island, NY), 80 mg of gentamicin/ml (Sigma-Aldrich, St. Louis, MO) and 300 mg/ml glutamine (complete medium).
Drug Treatment
PBMC, monocytes, B cells and T cells isolated from HIV-1 positive donors were treated with cocaine (Sigma-Aldrich) at 1µM for 48 hr or methamphetamine hydrochloride (Sigma-Aldrich) at 100 µM for 24 hr. Control cells were treated with complete media alone. The concentrations of cocaine and methamphetamine used were based on previous dose response studies that produced a maximum biological response without causing toxicity to the target cells and also were based on published studies (11–13). The concentrations of cocaine and methamphetamine are comparable to levels found in the blood, urine or tissue samples of users which range from ≤1 µM to 600 µM (16–21).
2D DIGE
The Ettan DIGE technique (GE Healthcare) was used to detect differences in protein abundance between normal and experimental samples. The Ettan DIGE system uses three CyDye DIGE fluors (Cy2, Cy3, Cy5), each with a unique fluorescent wavelength, matched for mass and charge. CyDyes form a covalent bond with the free epsilon amino group on lysine residues from the sample proteins. CyDyes label approximately 2% of the lysine residues. This system allows for two experimental samples and an internal standard to be simultaneously separated on the same gel. The internal standard is comprised a pool of an equal amount of all the experimental samples. The use of an internal standard facilitates accurate inter-gel matching of spots, and allows for data normalization between gels to minimize gel to gel experimental variability (22).
Sample preparation
After stimulation, cells were washed 2 times with 1X PBS (Invitrogen, Grand Island, NY). Total protein was extracted using standard cell lysis buffer [30 mM TrisCl; 8 M Urea; 4% (w/v) 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), adjusted to pH 8.5] for 10 min on ice. The cell lysate was centrifuged at 4°C for 10 min at 12000 g and the lysate was further purified by precipitation with chloroform/methanol as described (23). Cell lysates were resuspended in standard cell lysis buffer. Final cell lysate protein concentrations were determined with Bio-Rad Coomassie Protein Reagent (Bio-Rad, Hercules, CA) and used for DIGE analysis.
Sample labeling
All reagents used were from GE Healthcare. Briefly, 50 µg of cell lysate was labeled with 400 pmol of either Cy3 or Cy5 or Cy2 (Cy 2 was used to label the internal standard) on ice for 30 min and then quenched with a 50-fold molar excess of free lysine. Cy3, Cy5, Cy2 labeled samples and unlabeled protein (500–800 µg) were combined. An equal volume of 2X sample buffer [8 M Urea; 2% (v/v) Pharmalytes 3-10; 2% (w/v) dithiothreitol (DTT); 4% (w/v) CHAPS] was added and incubated on ice for 10 min. The total volume of sample was adjusted to 450 µl with rehydration buffer [4% (w/v) CHAPS; 8 M Urea; 1% (v/v) Pharmalytes 3-10 nonlinear (NL); 13 mM DTT].
DIGE
Samples were applied to immobilized pH gradient (IPG) strips (24cm, pH 3-10 NL), and absorbed by active rehydration at 30 V for 13 hr. Isoelectric focusing was carried out using an IPGphor IEF system with a three phase program; first phase at 500 V for 1 hr, second phase at 1000 V for 1 hr, and third phase (linear gradient) 8000 to 64000 V for 2 hr (50 uA maximum per strip). Prior to separation in the second dimension, strips were equilibrated for 15 min in equilibration buffer I [50 mM Tris-HCl, 6 M Urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.5% (w/v) DTT]. The strips were again equilibrated for 15 min in equilibration buffer II [50 mM Tris-HCl, 6 M Urea, 30% (v/v) glycerol, 2% (w/v) SDS, 4.5% (w/v) iodoacetamide] and transferred onto 18×20 cm, 12.5% uniform polyacrylamide gels poured between low fluorescence glass plates. Gels were bonded to inner plates using Bind-Silane solution according to the manufacturer’s protocol. Strips were overlaid with 0.9% agarose in 1X running buffer containing bromophenol blue and were run for 16 hr (1.8 W per gel) overnight at 15°C, in the Ettan DALT electrophoresis system.
Image acquisition
Fluorescent images of each CyDye (Cy3, Cy5, Cy2) were acquired using a Typhoon 9410 variable mode imager. After scanning, gels were fixed in 30% (v/v) methanol, 7.5% (v/v) acetic acid for 3 hr and stained overnight at room temperature with SYPRO-Ruby dye (Molecular Probes, Eugene, OR). Gels were de-stained in water and then scanned using the Typhoon 9410 scanner.
Image analysis
Images were processed in ImageQuant v5.2 software (GE Healthcare), and imported into DeCyder differential in-gel analysis (DIA) software v5.0 (GE Healthcare) for spot detection and normalization of spot intensities within each gel. Intergel matching was performed using the biological variation analysis (BVA) component of DeCyder software for cross-gel statistical analysis. Standardized protein abundance was calculated by dividing each Cy3 or Cy5 spot volume by the corresponding Cy2 standard spot volume (internal control) within each gel, and the difference in standardized abundance between control and drug-treated PBMC was expressed as the average volume ratio (data represented as % change from control). Statistical analysis (Student's t-test) was performed on spots matched across gels. Protein spots that showed statically significant differences between the control and drug-treated samples were picked using the Ettan Spot Picker (22) for subsequent mass spectrometry.
High performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)
In gel digestion of excised spots and HPLC-MS/MS were performed as described by Breci et al. 2005 (24). Briefly, gel slices were destained (25) and digested with trypsin (26). The tryptic peptides were extracted with 5% formic acid/50% CH3CN. HPLC was performed using a microbore system (Surveyor, ThermoFinnigan, San Jose, CA). The HPLC column eluate was directed into a ThermoFinnigan LCQ Deca XP Plus ion trap mass spectrometer. Automated peak recognition, dynamic exclusion, and daughter ion scanning of the top two most intense ions were performed using Xcalibur software (27). Spectra were scanned over the range 400–1400 mass units. MS/MS data were analyzed using SEQUEST, a computer program that allows the correlation of experimental data with theoretical spectra generated from known protein sequences. A preliminary positive peptide identification for a doubly-charged peptide was based upon a correlation factor (Xcorr) greater than 2.5, a delta cross-correlation factor (dCn) greater than 0.1 (indicating a significant difference between the best match reported and the next best match), a high preliminary scoring, and a minimum of one tryptic peptide terminus. For triply-charged peptides the correlation factor threshold was set at 3.5. All matched peptides were confirmed by visual examination of the spectra, and all spectra were searched against the latest version of the public, non-redundant protein database of the National Center for Biotechnology Information (NCBI) (28, 29).
RNA extraction and real time, quantitative PCR (Q-PCR)
Cytoplasmic RNA was extracted using TRIzol from Invitrogen (30). The final RNA pellet was dried and resuspended in diethyl pyrocarbonate (DEPC) water and the concentration of RNA was determined using a spectrophotometer at 260 nm. Any DNA contamination in the RNA preparation was removed by treating the RNA with DNAse (1 IU/µg of RNA, Promega, Madison WI) for 2 hr at 37°C, followed by proteinase K digestion at 37°C for 15 min and subsequent extraction with phenol/chloroform and NH4OAc/ETOH precipitation. The isolated RNA was stored at −70°C until used. DNA contamination of the RNA preparation was checked by including a control in which reverse transcriptase enzyme was not added to the PCR amplification procedure. Relative abundance of each mRNA species was assessed using the SYBR green master mix from Stratagene (La Jolla, CA) to perform Q-PCR. Differences in threshold cycle number were used to quantify the relative amount of PCR target contained within each tube. Relative mRNA species expression was quantitated and expressed as transcript accumulation index (TAI = 2−(ΔΔCT)), calculated using the comparative CT method. All data were controlled for quantity of RNA input by performing measurements on an endogenous reference gene, β-actin (31).
Statistics
For gene expression data, statistical significance was determined using a Student’s t-test (SPSS Inc.).
Results
Cocaine differentially modulates the expression of proteins in PBMC isolated from HIV-1 positive donors
Figure 1 is a representative 2D gel image of SYPRO Ruby dye stained proteins. Comparing standardized protein abundance data generated from the Cy3, Cy5 and Cy2 images (DeCYDER software) several protein spots were differentially expressed between cocaine treated and untreated, control PBMC. These protein spots were excised from the SYPRO Ruby stained gel and identified by HPLC-MS/MS. The protein spots that yielded positive identification are shown in Figure 1; they are labeled with arbitrary spot numbers and their identities are listed in Table I. Proteins that had a significant increase in expression were poly(rC) binding protein 1, vimentin, triosephosphate isomerase 1, chromobox homolog 3, sorcin, and galectin-1. Proteins that had a significant decrease in expression were proteasome α1 subunit, heat shock 70kDa protein 5 (HSP70p5), β globin, tubulin, rho GDP dissociation inhibitor-α (rho GDI α), rho GDP dissociation inhibitor-β (rho GDI β), tumor protein D54, proteasome α3 subunit, calpain, tyrosine 3-monooxygenase-tryptophan 5-monooxygenase activation protein, peroxiredoxin 6, and talin 1.
Figure 1.
Two-dimensional gel electrophoresis of cocaine-induced, differentially expressed proteins in PBMC isolated from HIV-1 positive donors. This is a representative 2D SYPRO-Ruby stained gel image (n = 4 independent experiments). Arbitrary spot numbers indicate statistically significant (Student’s t-test), differentially expressed proteins. The pH increases from left to right and the molecular mass decreases from the top to the bottom of the gels.
Table I.
PBMC isolated from HIV-1 positive subjects were cultured with and without cocaine (1 µM) for 48 hr (n = 4 independent experiments). Data represent statistically significant differentially expressed proteins (Student’s t-test) that were identified using HPLC-MS/MS (all proteins had an expect score >10). Data are represented as protein name, gene accession number (Gi No.), theoretical mass, theoretical isoelectric point (pI), ratio and significance. Theoretical mass and pI were calculated using: http://au.expasy.org/tools/pi_tool.html.
| Spot Number |
Protein name | Accession Number |
Theoretical mass |
Theoretical pI |
ratio | p value |
|---|---|---|---|---|---|---|
| 1623 | poly(rC) binding protein 1 | gi|6754994| | 37497.81 | 6.66 | 1.78 | 0.002 |
| 1812 | vimentin | gi|2119204| | 53651.68 | 5.06 | 1.53 | 0.001 |
| 2397 | triosephosphate isomerase 1 | gi|4507645| | 26669.49 | 6.45 | 1.59 | 0.005 |
| 2596 | chromobox homolog 3 | gi|6680860| | 19752.13 | 4.96 | 1.38 | 0.01 |
| 2653 | sorcin | gi|4507207| | 21676.38 | 5.32 | 1.42 | 0.002 |
| 2653 | galectin 1 | gi|4504981| | 14715.70 | 5.33 | 1.42 | 0.002 |
| 1543 | integrin α-IIb | gi|124951| | 113390.90 | 5.21 | −1.35 | 0.001 |
| 1773 | proteasome α 1 subunit | gi|23110935| | 30239.44 | 6.51 | −1.22 | 0.003 |
| 1596 | heat shock 70kDa protein 5 (HSP70 p5) |
gi|16507237| | 72332.96 | 5.07 | −1.41 | 0.05 |
| 2058 | β globin | gi|4504349| | 15998.41 | 6.74 | −1.64 | 0.042 |
| 2051 | tubulin | gi|20903441| | 50151.63 | 4.94 | −1.20 | 0.035 |
| 2282 | rho GDP dissociation inhibitor- α (rho GDI α) |
gi|4757768| | 23207.11 | 5.03 | −1.35 | 0.001 |
| 2282 | Tumor protein D54 | gi|20141658| | 22237.73 | 5.26 | −1.35 | 0.001 |
| 2287 | rho GDP dissociation inhibitor- β(rho GDI β) |
gi|10835002| | 22988.01 | 5.10 | −1.31 | 0.006 |
| 2308 | proteasome α 3 subunit | gi|4506183| | 28433.23 | 5.19 | −1.41 | 0.002 |
| 2385 | calpain | gi|4502565| | 28315.71 | 5.05 | −1.41 | 0.002 |
| 2385 | tyrosine 3- monooxygenase/tryptophan 5- monooxygenase activation protein |
gi|4507949| | 28082.40 | 4.76 | −1.41 | 0.002 |
| 2408 | peroxiredoxin 6 | gi|4758638| | 25034.99 | 6.00 | −1.62 | 0.035 |
| 2408 | talin 1 | gi|14916725| | 269717.94 | 5.72 | −1.62 | 0.035 |
Methamphetamine differentially modulates the expression of proteins in PBMC isolated from HIV-1 positive donors
Figure 2 is a representative 2D gel image of SYPRO Ruby dye stained proteins. Comparing standardized protein abundance data generated from the Cy3, Cy5 and Cy2 images several proteins spots were differentially expressed between methamphetamine treated and untreated control PBMC cultures isolated from HIV-1 positive donors. These protein spots were excised from the SYPRO Ruby stained gel and identified by HPLC-MS/MS and are shown in Figure 2, labeled with arbitrary spot numbers. Protein identities are listed in Table II. The identified spots that had increased protein expression were: vimentin, lactate dehydrogenase, calponin 2, fibrinogen gamma chain, RNA-binding protein regulatory subunit, transgelin 2, poly(rC) binding protein 1, proteasome α3 subunit, and galectin-1. The identified spots that had decreased protein expression were: tubulin, HSP70p5, glutathione-S-transferase, adenine phosphoribosyltransferase, erythrocyte band 7 integral membrane protein, superoxide dismutase, and peroxiredoxin 6.
Figure 2.
Two-dimensional analyses of methamphetamine-induced, differentially expressed proteins in PBMC isolated from HIV-1 positive donors. This is a representative 2D SYPRO-Ruby stained gel image (n = 4 independent experiments). Arbitrary spot numbers indicate statistically significant (Student’s t-test), differentially expressed proteins. The pH increases from left to right and the molecular mass decreases from the top to the bottom of the gels.
Table II.
PBMC isolated from HIV-1 positive subjects were cultured with and without methamphetamine (100 µm) for 24 hr. Data represent statistically significant differentially expressed proteins (Student’s t-test) that were identified using HPLC-MS/MS (all proteins had an expect score >10). Data are represented as protein name, gene accession number (Gi No.), theoretical mass, theoretical isoelectric point (pI), ratio and significance. Theoretical mass and pI were calculated using: http://au.expasy.org/tools/pi_tool.html.
| Spot # |
Protein Name | Gi | Theoretical mass |
Theoretical pI |
ratio | p value |
|---|---|---|---|---|---|---|
| 1108 | vimentin | gi|62414289| | 53651.68 | 5.06 | 1.59 | 0.033 |
| 1586 | lactate dehydrogenase | gi|32693754| | 36557.53 | 8.46 | 1.53 | 0.026 |
| 1597 | calponin 2 | gi|4758018| | 33697.05 | 6.94 | 2.18 | 0.05 |
| 1737 | fibrinogen gamma chain | gi|182439| | 44707.05 | 6.56 | 1.72 | 0.05 |
| 2068 | RNA-binding protein regulatory subunit |
gi|14198257| | 19847.01 | 6.33 | 1.78 | 0.007 |
| 2035 | transgelin 2 | gi|4507357| | 22391.45 | 8.41 | 1.59 | 0.025 |
| 1309 | poly(rC) binding protein 1 | gi|6754994| | 37497.81 | 6.66 | 1.64 | 0.073 |
| 1735 | proteasome α 3 subunit | gi|23110935| | 30239.44 | 6.51 | 1.63 | 0.041 |
| 2053 | galectin 1 | gi|4504981| | 14715.70 | 5.33 | 1.57 | 0.001 |
| 1726 | tubulin | gi|20903441| | 50151.63 | 4.94 | −1.87 | 0.05 |
| 1732 | heat shock 70kDa protein 5 (HSP70 p5) |
gi|16507237| | 72332.96 | 5.07 | −1.50 | 0.05 |
| 1773 | glutathione-S-transferase | gi|4758484| | 27565.86 | 6.24 | −1.36 | 0.05 |
| 2047 | adenine phosphoribosyltransferase |
gi|4502171| | 19607.77 | 5.78 | −1.47 | 0.01 |
| 2047 | erythrocyte band 7 integral membrane protein |
gi|114823| | 31730.80 | 7.71 | −1.47 | 0.01 |
| 2050 | superoxide dismutase | gi|34707| | 22089.00 | 6.86 | −2.16 | 0.027 |
| 2050 | peroxiredoxin 6 | gi|4758638| | 25034.99 | 6.00 | −2.16 | 0.035 |
For all 2D gels, several weak protein spots could not be identified due to insufficient amounts for identification and therefore are not shown in Figure 1 and Figure 2.
Modulation of gene expression
To confirm our proteomics data and demonstrate that gene expression correlates with protein synthesis, we investigated the effect of cocaine or methamphetamine on the expression of mRNA levels of specific genes by Q-PCR analysis using the primers listed in Table III. Effects of cocaine: Figure 3 shows that cocaine treatment had no effect on 18s RNA expression used as control RNA. Furthermore, cocaine significantly increased gene expression of vimentin, poly(rc) binding protein, and galectin-1 in PBMC isolated from HIV-1 positive donors while significantly decreasing gene expression of HSP70p5, rho GDI α, rho GDI β and peroxiredoxin 6. Cocaine induced changes in gene expression are reflective of changes in protein expression. Effects of methamphetamine: Figure 4 show that methamphetamine treatment had no effect on 18s RNA expression used as control RNA. Methamphetamine significantly increased gene expression for vimentin, poly(rc) binding protein, and galectin-1 while significantly decreasing gene expression for HSP70p5, glutathione-S-transferase, superoxide dismutase, and peroxiredoxin 6 in PBMC isolated from HIV-1 positive donors.
Table III.
Primer sequences for Real Time Q-PCR
| Primer | Primer sequences |
|---|---|
| β-actin | 5’, 5’-TGACGGGGTCACCCACACTGTGCCCATCTA-3’ 3’, 5-AGTCATAGTCCGCCTAGAAGCATTTGCGGT-3’ |
| galectin-1 | 5’ 5'-CTC TCG GGT GGA GTC TTC TG-3’ 3’, 5-GAA GGC ACT CTC CAG GTT TG-3’ |
| glutathione-S- transferase |
5’, 5’-AAG GCC CTG AAA ACC AGA AT-3’ 3’ 5'-GCC TCC ATG ACT GCG TTA TT-3’ |
| HSP70 p5 | 5’ 5'-TAG CGT ATG GTG CTG CTG TC-3’ 3’ 5'-TTT GTC AGG GGT CTT TCA CC-3’ |
| peroxiredoxin 6 | 5’, 5’- GGA TGG GGA TAG TGT GAT GG-3’ 3’, 5’- CTG ACA TCC TCT GGC TCA CA-3’ |
| poly(rC) binding protein |
5’, 5’-GGA AGC ATC ATT GGG AAG AA-3’ 3’, 5’-TCT TCC TCC AGC TTG TCG AT-3’ |
| rho GDI α | 5’, 5’- GAG CCT GCG AAA GTA CAA GG-3’ 3’, 5’- TCC TTC AGC ACA AAC GAC TG-3’ |
| rho GDI β | 5’, 5’- CCT ACA GGA CTG GGG TGA AA-3’ 3’, 5’- GAG CCT CCT CAA CTG GAG TG-3’ |
| superoxide dismutase |
5’, 5’-AGG GCA TCA TCA ATT TCG AG-3’ 3’ 5'-ACA TTG CCC AAG TCT CCA AC-3’ |
| vimentin | 5’, 5’-GAG AAC TTT GCC GTT GAA GC-3’ 3’ 5'-TCC AGC AGC TTC CTG TAG GT-3’ |
| 18S | Purchased from Ambion (Austin, TX) |
Figure 3.
Cocaine-induced changes in gene expression measured by Q-PCR in PBMC isolated from HIV-1 positive donors. Data are presented as the mean ± SD of 4 independent experiments; *p ≤ 0.001, # p≤ 0.01
Figure 4.
Methamphetamine-induced changes in gene expression measured by Q-PCR in PBMC isolated from HIV-1 positive donors. Data are presented as the mean ± SD of 4 independent experiments; * p≤ 0.001, # p≤ 0.01
Modulation of gene expression in PBMC subpopulations
To define the specific cell populations whose gene expression was selectively modulated by drugs of abuse, monocytes, B cells and T cells were isolated from PBMC obtained from HIV-1 positive donors. Cell subpopulations were subsequently treated with cocaine (1 µM, 48 hr) or methamphetamine (100 µM, 24 hr) and the expression of mRNA levels of the genes in PBMC previously shown to be modulated by cocaine and methamphetamine was investigated by Q-PCR analysis. Effects of cocaine: In both monocytes and T cells (Figure 5a & 5b) cocaine significantly increased gene expression of vimentin, poly(rc) binding protein, and galectin-1 while significantly decreasing gene expression of HSP70p5 and peroxiredoxin 6. Cocaine had no significant effect on gene expression in B cells (data not shown). Effects of methamphetamine: Methamphetamine significantly increased gene expression of vimentin, poly(rc) binding protein, and galectin-1 in both monocytes and T cells (Figure 6a & 6b). Furthermore, a significant decrease in gene expression of HSP70p5 and peroxiredoxin 6 was observed in monocytes and T cells from HIV-1 positive donors (Figure 6a & 6b). Methamphetamine had no significant effect on gene expression in B cells (data not shown). Therefore, the effects of drugs of abuse are primarily on monocytes and T cells, the primary targets of HIV-1, from HIV-1 positive donors.
Figure 5.
(a) Cocaine-induced changes in gene expression measured by Q-PCR in monocytes isolated from HIV-1 positive donors. Data are presented as the mean ± SD of 4 independent experiments; *p ≤ 0.001, # p≤ 0.01. (b) Cocaine-induced changes in gene expression measured by Q-PCR in T cells isolated from HIV-1 positive donors. Data are presented as the mean ± SD of 4 independent experiments; * p≤ 0.001, # p≤ 0.01
Figure 6.
(a) Methamphetamine-induced changes in gene expression in measured by Q-PCR in monocytes isolated from HIV-1 positive donors. Data are presented as the mean ± SD of 4 independent experiments; *p ≤ 0.001, # p≤ 0.01. (b) Methamphetamine-induced changes in gene expression measured by Q-PCR in T cells isolated from HIV-1 positive donors. Data are presented as the mean ± SD of 4 independent experiments; * p≤ 0.001, # p≤ 0.01
Discussion
Drug abuse has long been recognized as a significant co-morbidity associated with HIV-1 infections. In this study we sought to gain insight into the molecular mechanisms underlying the effects of drug abuse on progression of HIV-1 infections. Specifically, we examined changes in the proteome of PBMC from HIV-1 infected donors in response to treatment with the widely used, addictive drugs, cocaine and methamphetamine. Our data show that several functionally important classes of proteins were differentially regulated. The potential relevance of the differential expression of select regulated proteins is discussed below.
Heat shock proteins (HSPs), also known as stress proteins, belong to the family of molecular chaperones that can be induced upon cellular injury. HSPs are classified by their molecular weight, comprising of six general families: HSP110, HSP90, HSP70, HSP60, small molecular weight Hsps, and immunophilins (32, 33). HSPs have diverse functions including chaperone activity, regulation of redox state and regulation of protein turnover (32–34). HSP70 is incorporated into the membrane of HIV-1, HIV-2 and simian immunodeficiency virus (SIV) virions (35) and may affect the nuclear import of the HIV-1 preintegration complex (36). Overexpression of HSP70 decreases HIV-1 Vpr protein induced G2 arrest and apoptosis in 293T-632 cells which could be reversed with HSP70 RNA interference (37). These studies suggest that HSP70 is a novel, anti-HIV-1 innate immunity factor that targets HIV-1 Vpr (37, 38). This study demonstrates that cocaine and methamphetamine both decrease the expression of heat shock 70kDa protein 5 in PBMC, monocytes and T cells isolated from HIV-1 positive donors thereby supporting the premise that cocaine and methamphetamine suppress this innate immunity factor.
Vimentin is an intermediate filament protein that plays a role in mechanical and biological functions such as cell contractility, migration, stiffening, and proliferation (39). HIV-1 utilizes the host cytoskeletal system for infection and replication. HIV-1 and HIV-2 proteases have been shown to cleave vimentin (40–43). Furthermore, cleavage of vimentin by HIV-1 proteases is necessary for changes in chromatin organization and distribution induced by HIV-1 (44). In HeLa cells, the HIV-1 viral infectivity factor (Vif) colocalizes with vimentin in perinuclear aggregates (45, 46). Additionally, vimentin expression was shown to be decreased in SVGA-Tat expressing cells (47). Both cocaine and methamphetamine increase the expression of vimentin in PBMC, monocytes and T cells isolated from HIV-1 positive donors. An increase in expression of vimentin may play a role in facilitating the spread of HIV-1 infection to neighboring cells.
Cocaine and methamphetamine both down-regulate the antioxidant protein, peroxiredoxin 6. Previous studies have shown that peroxiredoxins are capable of inhibiting HIV-1 infection and members of the peroxiredoxin family, NKEF-A or NKEF-B inhibit HIV-1 replication in CD8+ T cells (48). Our studies support the premise that drugs of abuse increase susceptibility to and progression of HIV-1 infections by down-reulating the expression of the antioxidant protein, peroxiredoxin 6, which also has anti-HIV-1 activities.
We also found that members of the family of small GTP-binding proteins, RhoGDI alpha and RhoGDI beta, were down-regulated by cocaine treatment of PBMC isolated from HIV-1 positive patients. These proteins stabilize the inactive GDP-bound form of GTPases, preventing the release of GDP and the binding of GTP (49). GTPAses are necessary for HIV-1 replication (50–52), therefore our results indicate that cocaine-induced down-regulation of RhoGDI synthesis may enhance viral replication by allowing continual activation of GTPases.
Antioxidants such as superoxide dismutase are an important defense for cells. Superoxide dismutase converts superoxide to hydrogen peroxide, preventing the formation of reactive oxygen species. Studies demonstrate that a high activity of endogenous antioxidants may have a protective role on CD4+ T-cells, which may limit HIV-1 infection (53). Furthermore, cultured mature neurons transduced with rSV40 vectors carrying human SOD1 were protected against HIV-1 gp120 induced apoptosis. (54). This study demonstrates that methamphetamine decreases the production of superoxide dismutase. These data and previous studies suggest that methamphetamine treatment reduces the ability of PBMC to inhibit HIV-1 infection.
Galectin-1 is a member of a family of lectins with affinity for β-galactosidase that are defined by a shared amino acid sequence in their carbohydrate recognizing domain. Galectin-1 is widely expressed in the tissues of mammals including the lung, brain, heart, spleen and lymph nodes (55). Galectin-1 is located both extracellularly and intracellularly. Galectin-1 modulates cell proliferation, apoptosis, cell cycle arrest, cell-matrix adhesion, and cell to cell adhesion (55, 56). Previous studies demonstrated that galectin-1 acts as a soluble HIV-1 binding protein that can stabilize virus-cell interactions and promote virus replication in PBMC, CD4+ T cells, and monocyte derived macrophages (57, 58). Our data demonstrate that both cocaine and methamphetamine up-regulate the expression of galectin-1 in PBMC, monocytes and T cells isolated from HIV-1 positive donors, thereby enhancing HIV-1 infection by providing a mechanism for virus-to-cell interactions.
Conclusion
Our results show that cocaine and methamphetamine differentially regulate the synthesis of several specific proteins in PBMC, monocytes and T cells isolated from HIV-1 positive donors. However, the functions of these proteins with respect to HIV-1 disease progression remain to be clearly delineated. Many of these proteins have been reported to be involved in the pathogenesis of HIV-1 infections and may eventually serve as either biomarkers of disease progression or as unique targets for therapy in drug abusing, HIV-1 infected patients.
Acknowledgements
K01 DA024577
Kaleida Health Foundation
References
- 1.UNAIDS. 2008
- 2.Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2006 ( www.avert.org/statsum.htm)
- 3.NIDA Info Facts. 2008
- 4.Substance Abuse and Mental Health Services Administration, Results from the 2007 National Survey on Drug Use and Health: National Findings. 2008 September
- 5.Mohri H, Markowitz Me. In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J. Acquir. Immune. Defic. Syndr. 2008;48(5):511–521. doi: 10.1097/QAI.0b013e31817ecb31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR. Acceleration of HIV dementia with methamphetamine and cocaine. J. Neurovirol. 2001;7(1):66–71. doi: 10.1080/135502801300069737. [DOI] [PubMed] [Google Scholar]
- 7.Duncan R, Shapshak P, Page JB, Chiappelli F, McCoy CB, Messiah SE. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV infected African American women. Front. Biosci. 2007;12:1488–1495. doi: 10.2741/2162. [DOI] [PubMed] [Google Scholar]
- 8.Cook JA, Burke-Miller JK, Cohen MH, Cook RL, Vlahov D, Wilson TE, Golub ET, Schwartz RM, Howard AA, Ponath C, Plankey MW, Levine AM, Grey DD. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008;22(11):1355–1363. doi: 10.1097/QAD.0b013e32830507f2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Peterson PK, Gekker G, Schut R, Hu S, Balfour HH, Jr, Chao CC. Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection. Adv. Exp. Med. Biol. 1993;335:181–188. doi: 10.1007/978-1-4615-2980-4_26. [DOI] [PubMed] [Google Scholar]
- 10.Peterson PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH., Jr Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J. Immunol. 1991;146(1):81–84. [PubMed] [Google Scholar]
- 11.Nair MP, Mahajan SD, Schwartz SA, Reynolds J, Whitney R, Bernstein Z, Chawda RP, Sykes D, Hewitt R, Hsiao CB. Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J. Immunol. 2005;174(11):6617–6626. doi: 10.4049/jimmunol.174.11.6617. [DOI] [PubMed] [Google Scholar]
- 12.Reynolds JL, Mahajan SD, Sykes DE, Schwartz SA, Nair MP. Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC) Biochim. Biophys. Acta. 2007;1774(4):433–442. doi: 10.1016/j.bbapap.2007.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, Wang YJ, Zhou L, Ho WZ. Methamphetamine enhances HIV infection of macrophages. Am. J. Pathol. 2008;172(6):1617–1624. doi: 10.2353/ajpath.2008.070971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J. Infect. Dis. 2003;188:1820–1826. doi: 10.1086/379894. [DOI] [PubMed] [Google Scholar]
- 15.Cachay ER, Moini N, Kosakovsky Pond SL, Pesano R, Lie YS, Aiem H, Butler DM, Letendre S, Mathews WC, Smith DM. Active Methamphetamine Use is Associated with Transmitted Drug Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors in Individuals with HIV Infection of Unknown Duration. Open AIDS J. 2007;1:5–10. doi: 10.2174/1874613600701010005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Lee YW, Hennig B, Yao J, Toborek M. Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. J. Neurosci. Res. 2001;66:583–591. doi: 10.1002/jnr.1248. [DOI] [PubMed] [Google Scholar]
- 17.Tallóczy Z, Martinez J, Joset D, Ray Y, Gácser A, Toussi S, Mizushima N, Nosanchuk J, Goldstein H, Loike J, Sulzer D, Santambrogio L. Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog. 2008;4(2):e28. doi: 10.1371/journal.ppat.0040028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Edwards DJ, Bowles SK. Protein binding of cocaine in human serum. Pharm. Res. 1988;5:440–442. doi: 10.1023/a:1015992502509. [DOI] [PubMed] [Google Scholar]
- 19.Takayasu T, Ohshima T, Nishigami J, Kondo T, Nagaon T. Screening and determination of methamphetamine and amphetamine in the blood, urine and stomach contents in emergency medical care and autopsy cases. J. Clin. Forensic Med. 1995;2:25–33. doi: 10.1016/1353-1131(95)90036-5. [DOI] [PubMed] [Google Scholar]
- 20.Kalasinsky KS, Bosy TZ, Schmunk GA, Reiber G, Anthony RM, Furukawa Y, Guttman M, Kish SJ. Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Sci Int. 2001;116:163–169. doi: 10.1016/s0379-0738(00)00368-6. [DOI] [PubMed] [Google Scholar]
- 21.Schepers RJF, Oyler JM, Joseph RE, Cone EJ, Moolchan ET, Huestis MA. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin. Chem. 2003;49:121–132. doi: 10.1373/49.1.121. [DOI] [PubMed] [Google Scholar]
- 22. http://www1.amershambiosciences.com/aptrix/upp00919.nsf/Content/Proteomics+DIGE+Protocols.
- 23.Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 1984;138(1):141–143. doi: 10.1016/0003-2697(84)90782-6. [DOI] [PubMed] [Google Scholar]
- 24.Breci L, Hattrup E, Keeler M, Letarte J, Johnson R, Haynes PA. Comprehensive proteomics in yeast using chromatographic fractionation, gas phase fractionation, protein gel electrophoresis, and isoelectric focusing. Proteomics. 2005;5(8):2018–2028. doi: 10.1002/pmic.200401103. [DOI] [PubMed] [Google Scholar]
- 25.Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis. 1999;20(3):601–605. doi: 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
- 26.Cooper B, Eckert D, Andon NL, Yates JR, Haynes PA. Investigative proteomics: identification of an unknown plant virus from infected plants using mass spectrometry. J. Am. Soc. Mass Spectrom. 2003;14(7):736–741. doi: 10.1016/S1044-0305(03)00125-9. [DOI] [PubMed] [Google Scholar]
- 27.Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M. Femtomole sequencing of proteins from polyacrylamide gels by nanoelectrospray mass spectrometry. Nature. 1996;379(6564):466–469. doi: 10.1038/379466a0. [DOI] [PubMed] [Google Scholar]
- 28.Haynes PA, Gygi SP, Figeys D, Aebersold R. Proteome analysis: biological assay or data archive? Electrophoresis. 1998;19(11):1862–1871. doi: 10.1002/elps.1150191104. [DOI] [PubMed] [Google Scholar]
- 29.Andon NL, Hollingworth S, Koller A, Greenland AJ, Yates JR, 3rd, Haynes PA. Proteomic characterization of wheat amyloplasts using identification of proteins by tandem mass spectrometry. Proteomics. 2002;2(9):1156–1168. doi: 10.1002/1615-9861(200209)2:9<1156::AID-PROT1156>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
- 30.Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
- 31.Shively L, Chang L, LeBon JM, Liu Q, Riggs AD, Singer-Sam J. Real-time PCR assay for quantitative mismatch detection. Biotechniques. 2003;34:498–502. doi: 10.2144/03343st01. [DOI] [PubMed] [Google Scholar]
- 32.Prohászka Z, Füst G. Immunological aspects of heat-shock proteins-the optimum stress of life. Mol. Immunol. 2004;41(1):29–44. doi: 10.1016/j.molimm.2004.02.001. [DOI] [PubMed] [Google Scholar]
- 33.Gullo CA, Teoh G. Heat shock proteins: to present or not, that is the question. Immunol. Lett. 2004;94(1–2):1–10. doi: 10.1016/j.imlet.2004.04.002. [DOI] [PubMed] [Google Scholar]
- 34.Wainberg Z, Oliveira M, Lerner S, Tao Y, Brenner BG. Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficiency virus type-1. Virology. 1997;233:364–373. doi: 10.1006/viro.1997.8618. [DOI] [PubMed] [Google Scholar]
- 35.Gurer C, Cimarelli A, Luban J. Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J. Virol. 2002;76:4666–4670. doi: 10.1128/JVI.76.9.4666-4670.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Agostini I, Popov S, Li J, Dubrovsky L, Hao T, Bukrinsky M. Heat-shock protein 70 can replace viral protein R of HIV-1 during nuclear import of the viral preintegration complex. Exp. Cell. Res. 2000;259:398–403. doi: 10.1006/excr.2000.4992. [DOI] [PubMed] [Google Scholar]
- 37.Iordanskiy S, Zhao Y, Dubrovsky L, Iordanskaya T, Chen M, Liang D, Bukrinsky M. Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J. Virol. 2004;78:9697–9704. doi: 10.1128/JVI.78.18.9697-9704.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Iordanskiy S, Zhao Y, DiMarzio P, Agostini I, Dubrovsky L, Bukrinsky M. Heat-shock protein 70 exerts opposing effects on Vpr-dependent and Vpr-independent HIV-1 replication in macrophages. Blood. 2004;104:1867–1872. doi: 10.1182/blood-2004-01-0081. [DOI] [PubMed] [Google Scholar]
- 39.Wang N, Stamenovic D. Mechanics of vimentin intermediate filaments. J. Muscle Res. Cell Motil. 2002;23(5–6):535–540. doi: 10.1023/a:1023470709071. [DOI] [PubMed] [Google Scholar]
- 40.Snásel J, Shoeman R, Horejsí M, Hrusková-Heidingsfeldová O, Sedlácek J, Ruml T, Pichová I. Cleavage of vimentin by different retroviral proteases. Arch. Biochem. Biophys. 2000;377(2):241–245. doi: 10.1006/abbi.2000.1776. [DOI] [PubMed] [Google Scholar]
- 41.Höner B, Shoeman RL, Traub P. Human immunodeficiency virus type 1 protease microinjected into cultured human skin fibroblasts cleaves vimentin and affects cytoskeletal and nuclear architecture. J. Cell. Sci. 1991;100(Pt 4):799–807. doi: 10.1242/jcs.100.4.799. [DOI] [PubMed] [Google Scholar]
- 42.Höner B, Shoeman RL, Traub P. Degradation of cytoskeletal proteins by the human immunodeficiency virus type 1 protease. Cell. Biol. Int. Rep. 1992;16(7):603–612. doi: 10.1016/s0309-1651(06)80002-0. [DOI] [PubMed] [Google Scholar]
- 43.Shoeman RL, Höner B, Stoller TJ, Kesselmeier C, Miedel MC, Traub P, Graves MC. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Natl. Acad. Sci. U S A. 1990;87(16):6336–6340. doi: 10.1073/pnas.87.16.6336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Shoeman RL, Hüttermann C, Hartig R, Traub P. Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells. Mol. Biol. Cell. 2001;12(1):143–154. doi: 10.1091/mbc.12.1.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Karczewski MK, Strebel K. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 1996;70(1):494–507. doi: 10.1128/jvi.70.1.494-507.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Henzler T, Harmache A, Herrmann H, Spring H, Suzan M, Audoly G, Panek T, Bosch V. Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. J. Gen. Virol. 2001;82(Pt 3):561–573. doi: 10.1099/0022-1317-82-3-561. [DOI] [PubMed] [Google Scholar]
- 47.Pocernich CB, Boyd-Kimball D, Poon HF, Thongboonkerd V, Lynn BC, Klein JB, Calebrese V, Nath A, Butterfield DA. Proteomics analysis of human astrocytes expressing the HIV protein Tat. Brain Res. Mol. Brain Res. 2005;133(2):307–316. doi: 10.1016/j.molbrainres.2004.10.023. [DOI] [PubMed] [Google Scholar]
- 48.Geiben-Lynn R, Kursar M, Brown NV, Addo MM, Shau H, Lieberman J, Luster AD, Walker BD. HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J. Biol. Chem. 2003;278(3):1569–1574. doi: 10.1074/jbc.M209964200. [DOI] [PubMed] [Google Scholar]
- 49.Ross EM. Coordinating speed and amplitude in G-protein signaling. Curr. Biol. 2008;18(17):R777–R783. doi: 10.1016/j.cub.2008.07.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Stantchev TS, Broder CC. Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors. Cytokine Growth Factor Rev. 2001;12(2–3):219–243. doi: 10.1016/s1359-6101(00)00033-2. [DOI] [PubMed] [Google Scholar]
- 51.Audoly G, Popoff MR, Gluschankof P. Involvement of a small GTP binding protein in HIV-1 release. Retrovirology. 2005;2:4. doi: 10.1186/1742-4690-2-48. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Lin YL, Mettling C, Portalès P, Réant B, Clot J, Corbeau P. G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes. J. Virol. 2005;79(12):7938–7941. doi: 10.1128/JVI.79.12.7938-7941.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Ibeh BO, Obidoa O, Uzoegwu PN. High plasma activity of endogenous antioxidants protect CD4+ T-cells in HIV-serodiscordant heterosexual partners in a Nigerian population. Int. J. STD AIDS. 2008;19(8):536–540. doi: 10.1258/ijsa.2008.008031. [DOI] [PubMed] [Google Scholar]
- 54.Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis. Gene Ther. 2006;13(23):1645–1656. doi: 10.1038/sj.gt.3302821. [DOI] [PubMed] [Google Scholar]
- 55.Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007;64(13):1679–1700. doi: 10.1007/s00018-007-7044-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE. Galectin-1 receptors in different cell types. J Biomed Sci. 2005;12(1):13–29. doi: 10.1007/s11373-004-8169-5. [DOI] [PubMed] [Google Scholar]
- 57.Mercier S, St-Pierre C, Pelletier I, Ouellet M, Tremblay MJ, Sato S. Galectin-1 promotes HIV-1 infectivity in macrophages through stabilization of viral adsorption. Virology. 2008;371(1):121–129. doi: 10.1016/j.virol.2007.09.034. [DOI] [PubMed] [Google Scholar]
- 58.Ouellet M, Mercier S, Pelletier I, Bounou S, Roy J, Hirabayashi J, Sato S, Tremblay MJ. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J Immunol. 2005;174(7):4120–4126. doi: 10.4049/jimmunol.174.7.4120. [DOI] [PubMed] [Google Scholar]






